Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Van den Eynde

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Cancers|November 27, 2025
Current Management of Locally Advanced Esophageal and Esophagogastric Junction Cancers: Clinical Evidence and Evolving StrategiesAndrea Di Donato, Marc Van den Eynde
Molecular Oncology|November 25, 2025
TREX1, a predator for treating MSI-H tumors?Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde
Gastroenterology Report|February 28, 2020
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Nicolas Huyghe, Paméla Baldin, Marc Van den Eynde
Clinical Colorectal Cancer|January 27, 2010
Is tailored adjuvant treatment for colon cancer possible?Marc Van den Eynde, Ahmad Awada, Alain Hendlisz
Biomolecules|May 16, 2023
Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic SettingJulien Pierrard, Geneviève Van Ooteghem, Marc Van den Eynde
Oncoimmunology|January 18, 2021
Multiverse of immune microenvironment in metastatic colorectal cancerMarc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, et al.
Cancers|May 14, 2022
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized MedicineNicolas Huyghe, Elena Benidovskaya, Philippe Stevens, et al.
Oncoimmunology|September 14, 2020
Metastasis immune-based scores predict patient survivalBernhard Mlecnik, Gabriela Bindea, Marc Van den Eynde, et al.
Clinical Colorectal Cancer|April 2, 2020
HER2 as a Predictive Biomarker and Treatment Target in Colorectal CancerAstrid De Cuyper, Marc Van Den Eynde, Jean-Pascal Machiels
Oncoimmunology|October 28, 2020
Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patientsPamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Cancers|November 27, 2025
Current Management of Locally Advanced Esophageal and Esophagogastric Junction Cancers: Clinical Evidence and Evolving StrategiesAndrea Di Donato, Marc Van den Eynde
Molecular Oncology|November 25, 2025
TREX1, a predator for treating MSI-H tumors?Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde
Gastroenterology Report|February 28, 2020
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Nicolas Huyghe, Paméla Baldin, Marc Van den Eynde
Clinical Colorectal Cancer|January 27, 2010
Is tailored adjuvant treatment for colon cancer possible?Marc Van den Eynde, Ahmad Awada, Alain Hendlisz
Biomolecules|May 16, 2023
Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic SettingJulien Pierrard, Geneviève Van Ooteghem, Marc Van den Eynde
Oncoimmunology|January 18, 2021
Multiverse of immune microenvironment in metastatic colorectal cancerMarc Van den Eynde, Bernhard Mlecnik, Gabriela Bindea, et al.
Cancers|May 14, 2022
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized MedicineNicolas Huyghe, Elena Benidovskaya, Philippe Stevens, et al.
Oncoimmunology|September 14, 2020
Metastasis immune-based scores predict patient survivalBernhard Mlecnik, Gabriela Bindea, Marc Van den Eynde, et al.
Clinical Colorectal Cancer|April 2, 2020
HER2 as a Predictive Biomarker and Treatment Target in Colorectal CancerAstrid De Cuyper, Marc Van Den Eynde, Jean-Pascal Machiels
Oncoimmunology|October 28, 2020
Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patientsPamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, et al.
Pageof 8